Evidence map›Paper›PMID 22111980›Full record

ArticleMolecular diagnosis & therapy2012

Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.

Yiannis Vasilopoulos, Marilena Manolika, Efterpi Zafiriou, Theologia Sarafidou, Vasilis Bagiatis, Sabine Krüger-Krasagaki, Androniki Tosca, Aikaterini Patsatsi, Dimitris Sotiriadis, Zissis Mamuris and 1 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Molecular diagnosis & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Pharmacogenomics of TNF inhibitors.Frontiers in immunology · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.International journal of molecular sciences · 2023
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Yiannis VasilopoulosDepartment of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece. iovasilopoulos@bio.uth.gr
Marilena Manolika
Efterpi Zafiriou
Theologia Sarafidou
Vasilis Bagiatis
Sabine Krüger-Krasagaki
Androniki Tosca
Aikaterini Patsatsi
Dimitris Sotiriadis
Zissis Mamuris
Angeliki Roussaki-Schulze
University of Thessaly · GRPapageorgiou General Hospital · GRUniversity Hospital of Heraklion · GRUniversity Hospital of Larissa · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough biologic therapies have revolutionized the treatment of psoriasis, patients exhibit a substantial heterogeneous response that could be due to complex genetic heterogeneity.

objectiveThe aim of this study was to investigate the possible influence of tumor necrosis factor-α (TNF), TNF receptor I (TNFRSF1A), and TNF receptor II (TNFRSF1B) gene polymorphisms on anti-TNF treatment responsiveness in psoriasis patients.

methodsA Greek multicenter collaboration was established to recruit a cohort of patients (n = 80) with psoriasis treated with anti-TNF drugs. Single nucleotide polymorphisms (SNPs) in TNF (-238G>A, -308G>A, -857C>T), TNFRSF1A (36A>G), and TNFRSF1B (676T>G) were genotyped by PCR-restriction fragment length polymorphism assays. SNPs and haplotypes, including stratification by comorbidity status, were analyzed for association with treatment response after 6 months of therapy, defined as a reduction in the Psoriasis Area and Severity Index (PASI) score by >75% (responders) or ≤50% (nonresponders).

resultsSixty-three patients (78.8%) were defined as responders (PASI score reduction >75%) and 17 patients (21.2%) were defined as nonresponders (PASI score reduction ≤50%). Carriage of TNF -857C or TNFRSF1B 676T alleles was associated with positive response to drug treatment in patients treated with etanercept (p = 0.002 and p = 0.001, respectively). None of the genotyped SNPs were associated with responsiveness to treatment with infliximab or adalimumab. Additionally, when patients were stratified by comorbidity status, none of the genotyped SNPs were alone associated with responsiveness to drug treatment.

conclusionThis study is the first in the field of psoriasis demonstrating a strong association between genetic markers and positive response to drug treatment. Validation of this result in larger studies, as well as analysis of other drug treatments, could provide the basis for individually tailored treatment, along with increased cost effectiveness and reduced unnecessary exposure to toxicity.

Indexed as

Polymorphism, Single NucleotideTumor Necrosis Factor InhibitorsAdultAntibodies, MonoclonalAnti-Inflammatory AgentsCohort StudiesFemaleGenetic Predisposition to DiseaseGenotypeGreeceHumansInfliximabMaleMiddle AgedPharmacogeneticsPsoriasisAntibodies, MonoclonalAnti-Inflammatory AgentsInfliximabReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IITNFRSF1A protein, humanTNFRSF1B protein, humanTumor Necrosis Factor InhibitorsTumor Necrosis Factors

Identifiers

PMID22111980
OpenAlexW1969848095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.